Analysts Offer Predictions for KTTA Q1 Earnings

Pasithea Therapeutics Corp. (NASDAQ:KTTA) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Pasithea Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Nik anticipates that the company will earn ($0.45) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. HC Wainwright also issued estimates for Pasithea Therapeutics’ Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at $0.48 EPS and Q4 2026 earnings at $0.48 EPS.

Pasithea Therapeutics (NASDAQ:KTTA) last announced its earnings results on Monday, March 30th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.71).

Other equities analysts have also issued reports about the company. Zacks Research raised Pasithea Therapeutics to a “hold” rating in a research report on Tuesday, December 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Friday, March 27th. Finally, Wall Street Zen raised shares of Pasithea Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, January 18th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Pasithea Therapeutics Stock Up 3.5%

Shares of NASDAQ KTTA opened at $0.77 on Thursday. Pasithea Therapeutics has a fifty-two week low of $0.28 and a fifty-two week high of $3.79. The business has a 50 day moving average price of $0.80 and a two-hundred day moving average price of $0.85. The firm has a market cap of $19.20 million, a PE ratio of -0.22 and a beta of 0.25.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Two Sigma Investments LP acquired a new position in shares of Pasithea Therapeutics in the 3rd quarter worth approximately $26,000. Geode Capital Management LLC lifted its stake in Pasithea Therapeutics by 113.9% during the fourth quarter. Geode Capital Management LLC now owns 54,495 shares of the company’s stock worth $70,000 after purchasing an additional 29,020 shares during the last quarter. Jane Street Group LLC boosted its holdings in Pasithea Therapeutics by 137.0% in the fourth quarter. Jane Street Group LLC now owns 59,372 shares of the company’s stock worth $77,000 after purchasing an additional 34,319 shares during the period. Citadel Advisors LLC boosted its holdings in Pasithea Therapeutics by 43.7% in the third quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock worth $48,000 after purchasing an additional 20,483 shares during the period. Finally, AdvisorShares Investments LLC increased its stake in Pasithea Therapeutics by 33.1% during the third quarter. AdvisorShares Investments LLC now owns 257,696 shares of the company’s stock valued at $186,000 after purchasing an additional 64,149 shares during the last quarter. Institutional investors own 23.92% of the company’s stock.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.